IM Tixagevimab-Cilgavimab Trial
The proportion of participants with unquantifiable nasopharyngeal SARS-CoV-2 RNA differed significantly across days 3, 7, and 14 between the IM T-C and placebo arms after adjusting for pretreatment (day 0) values (joint 